Distinct inactivation of PI3K signalling by PTEN and 5-phosphatases

Advances in Biological Regulation

Volumn 52, Issue 1, 2012, Pages 205-213

  Leslie, Nick R ^a   Dixon, Miles J ^a   Schenning, Martijn ^a   Gray, Alex ^a   Batty, Ian H ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84863863498     PISSN: 22124926     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.advenzreg.2011.09.010     Document Type: Review

References (69)

1. Agoulnik I.U., Hodgson M.C., Bowden W.A., Ittmann M.M. INPP4B: the new kid on the PI3K block. Oncotarget 2011, 2:321-328.
2. Alessi D.R., Downes C.P. The role of PI 3-kinase in insulin action. Biochimica et Biophysica Acta 1998, 1436:151-164.
3. Alessi D.R., James S.R., Downes C.P., Holmes A.B., Gaffney P.R., Reese C.B., et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase B alpha. Current Biology 1997, 7:261-269.
4. Alimonti A., Carracedo A., Clohessy J.G., Trotman L.C., Nardella C., Egia A., et al. Subtle variations in Pten dose determine cancer susceptibility. Nature Genetics 2010, 42:454-458.
5. Arteaga C.L. Clinical development of phosphatidylinositol-3 kinase pathway inhibitors. Current Topics in Microbiology and Immunology 2010, 347:189-208.
6. Backers K., Blero D., Paternotte N., Zhang J., Erneux C. The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases. Advances in Enzyme Regulation 2003, 43:15-28.
7. Batty I.H., van der Kaay J., Gray A., Telfer J.F., Dixon M.J., Downes C.P. The control of phosphatidylinositol 3,4-bisphosphate concentrations by activation of the Src homology 2 domain containing inositol polyphosphate 5-phosphatase 2, SHIP2. The Biochemical Journal 2007, 407:255-266.
8. Berger A.H., Knudson A.G., Pandolfi P.P. A continuum model for tumour suppression. Nature 2011, 476:163-169.
9. Bielas S.L., Silhavy J.L., Brancati F., Kisseleva M.V., Al-Gazali L., Sztriha L., et al. Mutations in INPP5E, encoding inositol polyphosphate-5-phosphatase E, link phosphatidyl inositol signaling to the ciliopathies. Nature Genetics 2009, 41:1032-1036.
10. Blero D., Zhang J., Pesesse X., Payrastre B., Dumont J.E., Schurmans S., et al. Phosphatidylinositol 3,4,5-trisphosphate modulation in SHIP2-deficient mouse embryonic fibroblasts. The FEBS Journal 2005, 272:2512-2522.
11. Campa F., Yoon H.Y., Ha V.L., Szentpetery Z., Balla T., Randazzo P.A. A PH domain in the Arf GTPase-activating protein (GAP) ARAP1 binds phosphatidylinositol 3,4,5-trisphosphate and regulates Arf GAP activity independently of recruitment to the plasma membranes. The Journal of Biological Chemistry 2009, 284:28069-28083.
12. Carpten J.D., Faber A.L., Horn C., Donoho G.P., Briggs S.L., Robbins C.M., et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 2007, 448:439-444.
13. Carracedo A., Alimonti A., Pandolfi P.P. PTEN level in tumor suppression: how much is too little?. Cancer Research 2011, 71:629-633.
14. Carracedo A., Pandolfi P.P. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 2008, 27:5527-5541.
15. Copeland N.G., Jenkins N.A. Deciphering the genetic landscape of cancer-from genes to pathways. Trends in Genetics 2009, 25:455-462.
16. Davies M.A., Stemke-Hale K., Tellez C., Calderone T.L., Deng W., Prieto V.G., et al. A novel AKT3 mutation in melanoma tumours and cell lines. British Journal of Cancer 2008, 99:1265-1268.
17. Di Paolo G., De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006, 443:651-657.
18. Dixon M.J., Gray A., Boisvert F.M., Agacan M., Morrice N.A., Gourlay R., et al. A screen for novel phosphoinositide 3-kinase effector proteins. Molecular & Cellular Proteomics : MCP 2011, 10. doi: M110 003178.
19. Dowler S., Currie R.A., Campbell D.G., Deak M., Kular G., Downes C.P., et al. Identification of pleckstrin-homology-domain-containing proteins with novel phosphoinositide-binding specificities. The Biochemical Journal 2000, 351:19-31.
20. Downes C.P., Leslie N.R., Batty I.H., van der Kaay J. Metabolic switching of PI3K-dependent lipid signals. Biochemical Society Transactions 2007, 35:188-192.
21. Engelman J.A., Luo J., Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews Genetics 2006, 7:606-619.
22. Fedele C.G., Ooms L.M., Ho M., Vieusseux J., O'Toole S.A., Millar E.K., et al. Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancers. Proceedings of the National Academy of Sciences of the United States of America 2010, 107:22231-22236.
23. Frech M., Andjelkovic M., Ingley E., Reddy K.K., Falck J.R., Hemmings B.A. High affinity binding of inositol phosphates and phosphoinositides to the pleckstrin homology domain of RAC/protein kinase B and their influence on kinase activity. The Journal of Biological Chemistry 1997, 272:8474-8481.
24. Gewinner C., Wang Z.C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell. 2009, 16:115-125.
25. Godi A., Di Campli A., Konstantakopoulos A., Di Tullio G., Alessi D.R., Kular G.S., et al. FAPPs control Golgi-to-cell-surface membrane traffic by binding to ARF and PtdIns(4)P. Nature Cell Biology 2004, 6:393-404.
26. Greulich H. The genomics of lung adenocarcinoma: opportunities for targeted therapies. Genes &Cancer 2010, 1:1200-1210.
27. Harlan J.E., Hajduk P.J., Yoon H.S., Fesik S.W. Pleckstrin homology domains bind to phosphatidylinositol-4,5-bisphosphate. Nature 1994, 371:168-170.
28. Hawkins P.T., Anderson K.E., Davidson K., Stephens L.R. Signalling through Class I PI3Ks in mammalian cells. Biochemical Society Transactions 2006, 34:647-662.
29. Hodgson M.C., Shao L.J., Frolov A., Li R., Peterson L.E., Ayala G., et al. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Research 2011, 71:572-582.
30. Ivetac I., Gurung R., Hakim S., Horan K.A., Sheffield D.A., Binge L.C., et al. Regulation of PI(3)K/Akt signalling and cellular transformation by inositol polyphosphate 4-phosphatase-1. EMBO Reports 2009, 10:487-493.
31. Jacoby M., Cox J.J., Gayral S., Hampshire D.J., Ayub M., Blockmans M., et al. INPP5E mutations cause primary cilium signaling defects, ciliary instability and ciliopathies in human and mouse. Nature Genetics 2009, 41:1027-1031.
32. Kavran J.M., Klein D.E., Lee A., Falasca M., Isakoff S.J., Skolnik E.Y., et al. Specificity and promiscuity in phosphoinositide binding by pleckstrin homology domains. The Journal of Biological Chemistry 1998, 273:30497-30508.
33. Korkola J., Gray J.W. Breast cancer genomes-form and function. Current Opinion in Genetics & Development 2010, 20:4-14.
34. Lee J.S., Kim J.H., Jang I.H., Kim H.S., Han J.M., Kazlauskas A., et al. Phosphatidylinositol (3,4,5)-trisphosphate specifically interacts with the phox homology domain of phospholipase D1 and stimulates its activity. Journal of Cell Science 2005, 118:4405-4413.
35. Lemmon M.A. Membrane recognition by phospholipid-binding domains. Nature Reviews Molecular Cell Biology 2008, 9:99-111.
36. Lemmon M.A., Ferguson K.M. Signal-dependent membrane targeting by pleckstrin homology (PH) domains. The Biochemical Journal 2000, 350(Pt 1):1-18.
37. Leslie N.R., Foti M. Non-genomic loss of PTEN function in cancer: not in my genes. Trends in Pharmacological Sciences 2011, 32:131-140.
38. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947. (New York, NY).
39. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nature Reviews Drug Discovery 2009, 8:627-644.
40. Liu Q., Sasaki T., Kozieradzki I., Wakeham A., Itie A., Dumont D.J., et al. SHIP is a negative regulator of growth factor receptor-mediated PKB/Akt activation and myeloid cell survival. Genes & Development 1999, 13:786-791.
41. Ma K., Cheung S.M., Marshall A.J., Duronio V. PI(3,4,5)P3 and PI(3,4)P2 levels correlate with PKB/akt phosphorylation at Thr308 and Ser473, respectively; PI(3,4)P2 levels determine PKB activity. Cellular Signalling 2008, 20:684-694.
42. Maehama T., Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. The Journal of Biological Chemistry 1998, 273:13375-13378.
43. Manna D., Albanese A., Park W.S., Cho W. Mechanistic basis of differential cellular responses of phosphatidylinositol 3,4-bisphosphate- and phosphatidylinositol 3,4,5-trisphosphate-binding pleckstrin homology domains. The Journal of Biological Chemistry 2007, 282:32093-32105.
44. McConnachie G., Pass I., Walker S.M., Downes C.P. Interfacial kinetic analysis of the tumour suppressor phosphatase, PTEN: evidence for activation by anionic phospholipids. The Biochemical Journal 2003, 371:947-955.
45. Myers M.P., Pass I., Batty I.H., Van der Kaay J., Stolarov J.P., Hemmings B.A., et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proceedings of the National Academy of Sciences of the United States of America 1998, 95:13513-13518.
46. Network T.C.G.A.R. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068.
47. Norris F.A., Atkins R.C., Majerus P.W. The cDNA cloning and characterization of inositol polyphosphate 4-phosphatase type II. Evidence for conserved alternative splicing in the 4-phosphatase family. The Journal of Biological Chemistry 1997, 272:23859-23864.
48. Norris F.A., Majerus P.W. Hydrolysis of phosphatidylinositol 3,4-bisphosphate by inositol polyphosphate 4-phosphatase isolated by affinity elution chromatography. The Journal of Biological Chemistry 1994, 269:8716-8720.
49. Ooms L.M., Horan K.A., Rahman P., Seaton G., Gurung R., Kethesparan D.S., et al. The role of the inositol polyphosphate 5-phosphatases in cellular function and human disease. The Biochemical Journal 2009, 419:29-49.
50. 3-regulated PH domains from C. elegans to H. sapiens by model prediction and live imaging. Molecular Cell 2008, 30:381-392.
51. Premkumar L., Bobkov A.A., Patel M., Jaroszewski L., Bankston L.A., Stec B., et al. Structural basis of membrane targeting by the Dock180 family of Rho family guanine exchange factors (Rho-GEFs). The Journal of Biological Chemistry 2010, 285:13211-13222.
52. Rohrschneider L.R., Fuller J.F., Wolf I., Liu Y., Lucas D.M. Structure, function, and biology of SHIP proteins. Genes & Development 2000, 14:505-520.
53. Salmena L., Carracedo A., Pandolfi P.P. Tenets of PTEN tumor suppression. Cell 2008, 133:403-414.
54. Sasaki J., Kofuji S., Itoh R., Momiyama T., Takayama K., Murakami H., et al. The PtdIns(3,4)P(2) phosphatase INPP4A is a suppressor of excitotoxic neuronal death. Nature 2010, 465:497-501.
55. Shin H.W., Hayashi M., Christoforidis S., Lacas-Gervais S., Hoepfner S., Wenk M.R., et al. An enzymatic cascade of Rab5 effectors regulates phosphoinositide turnover in the endocytic pathway. The Journal of Cell Biology 2005, 170:607-618.
56. Sleeman M.W., Wortley K.E., Lai K.M., Gowen L.C., Kintner J., Kline W.O., et al. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nature Medicine 2005, 11:199-205.
57. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 1998, 95:29-39.
58. Steck P.A., Pershouse M.A., Jasser S.A., Yung W.K., Lin H., Ligon A.H., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nature Genetics 1997, 15:356-362.
59. Stephens L., Hawkins P. Signalling via class IA PI3Ks. Advances in Enzyme Regulation 2011, 51:27-36.
60. Suzuki A., Nakano T., Mak T.W., Sasaki T. Portrait of PTEN: messages from mutant mice. Cancer Science 2008, 99:209-213.
61. Taylor B.S., Schultz N., Hieronymus H., Gopalan A., Xiao Y., Carver B.S., et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010, 18:11-22.
62. Urick M.E., Rudd M.L., Godwin A.K., Sgroi D., Merino M., Bell D.W. PIK3R1 (p85alpha) is somatically mutated at high frequency in primary endometrial cancer. Cancer Research 2011, 71:4061-4067.
63. Vogt P.K., Kang S., Elsliger M.A., Gymnopoulos M. Cancer-specific mutations in phosphatidylinositol 3-kinase. Trends in Biochemical Sciences 2007, 32:342-349.
64. Watt S.A., Kimber W.A., Fleming I.N., Leslie N.R., Downes C.P., Lucocq J.M. Detection of novel intracellular agonist responsive pools of phosphatidylinositol 3,4-bisphosphate using the TAPP1 pleckstrin homology domain in immunoelectron microscopy. The Biochemical Journal 2004, 377:653-663.
65. Welch H.C., Coadwell W.J., Ellson C.D., Ferguson G.J., Andrews S.R., Erdjument-Bromage H., et al. P-Rex1, a PtdIns(3,4,5)P3- and Gbetagamma-regulated guanine-nucleotide exchange factor for Rac. Cell 2002, 108:809-821.
66. Wullschleger S., Wasserman D.H., Gray A., Sakamoto K., Alessi D.R. Role of TAPP1 and TAPP2 adaptor binding to PtdIns(3,4)P2 in regulating insulin sensitivity defined by knock-in analysis. The Biochemical Journal 2011, 434:265-274.
67. Yang X., Ongusaha P.P., Miles P.D., Havstad J.C., Zhang F., So W.V., et al. Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance. Nature 2008, 451:964-969.
68. Yu J.W., Mendrola J.M., Audhya A., Singh S., Keleti D., DeWald D.B., et al. Genome-wide analysis of membrane targeting by S. cerevisiae pleckstrin homology domains. Molecular Cell 2004, 13:677-688.
69. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.